Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (101-110 of 186) with videos related to

Pageof 19
Sort By:
Pharmacogenetics and Genomics|December 5, 2013
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469Jacqueline Ramírez, Tae Won Kim, Wanqing Liu, et al.
Archives of Toxicology|January 20, 2016
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinomaLucia Pellé, Monica Cipollini, Roman Tremmel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and CetuximabFederico Innocenti, Akram Yazdani, Naim Rashid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancerGiuseppe Toffoli, Erika Cecchin, Giampiero Gasparini, et al.
Cancer Research|November 3, 2018
Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with SorafenibDaniel J Crona, Andrew D Skol, Veli-Matti Leppänen, et al.
Cancer Causes & Control : CCC|May 20, 2019
Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D<sub>3</sub> levels and survival among patients with metastatic colorectal cancerChen Yuan, Lindsay Renfro, Pratibha B Ambadwar, et al.
Epigenetics|April 12, 2022
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)Lynn Symonds, Ming Yu, YuHong Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2014
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancerFederico Innocenti, Richard L Schilsky, Jacqueline Ramírez, et al.
Clinical Pharmacology and Therapeutics|December 24, 2019
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased PhenotypesAmy S Etheridge, Paul J Gallins, Dereje Jima, et al.
Research Square|April 1, 2024
Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapiesAkram Yazdani, Azam Yazdani, Raul Mendez-Giraldez, et al.
Pageof 19

Showing results (101-110 of 186) with videos related to

Sort By:
Pageof 19
Pharmacogenetics and Genomics|December 5, 2013
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469Jacqueline Ramírez, Tae Won Kim, Wanqing Liu, et al.
Archives of Toxicology|January 20, 2016
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinomaLucia Pellé, Monica Cipollini, Roman Tremmel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2022
Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and CetuximabFederico Innocenti, Akram Yazdani, Naim Rashid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancerGiuseppe Toffoli, Erika Cecchin, Giampiero Gasparini, et al.
Cancer Research|November 3, 2018
Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with SorafenibDaniel J Crona, Andrew D Skol, Veli-Matti Leppänen, et al.
Cancer Causes & Control : CCC|May 20, 2019
Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D<sub>3</sub> levels and survival among patients with metastatic colorectal cancerChen Yuan, Lindsay Renfro, Pratibha B Ambadwar, et al.
Epigenetics|April 12, 2022
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)Lynn Symonds, Ming Yu, YuHong Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2014
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancerFederico Innocenti, Richard L Schilsky, Jacqueline Ramírez, et al.
Clinical Pharmacology and Therapeutics|December 24, 2019
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased PhenotypesAmy S Etheridge, Paul J Gallins, Dereje Jima, et al.
Research Square|April 1, 2024
Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapiesAkram Yazdani, Azam Yazdani, Raul Mendez-Giraldez, et al.
Pageof 19